Newcastle disease virus induces pro-inflammatory conditions and type I interferon for counter-acting Treg activity. Nov 2011 - :1791-2423 [PMID:22102168] [Fournier P] [Arnold A] [Wilden H] [Schirrmacher V]
Importance of retinoic acid-inducible gene I and of receptor for type I interferon for cellular resistance to infection by Newcastle disease virus. Oct 2011 - :1791-2423 [PMID:21971670] [Fournier P] [Wilden H] [Schirrmacher V]
Analysis of three properties of Newcastle disease virus for fighting cancer: tumor-selective replication, antitumor cytotoxicity, and immunostimulation. Sep 2011 - Methods Mol. Biol.; 797:1940-6029 [PMID:21948477] [Fournier P] [Bian H] [Szeberényi J] [Schirrmacher V]
Targeting of IL-2 and GM-CSF immunocytokines to a tumor vaccine leads to increased anti-tumor activity. Apr 2011 - Int. J. Oncol.; 38(6):1791-2423 [PMID:21424118] [Fournier P] [Aigner M] [Schirrmacher V]
Antitumor vaccination by Newcastle Disease Virus Hemagglutinin-Neuraminidase plasmid DNA application: Changes in tumor microenvironment and activation of innate anti-tumor immunity. Jan 2011 - :1873-2518 [PMID:21172381] [Ni J] [Galani IE] [Cerwenka A] [Schirrmacher V] [Fournier P]
Transcriptome analysis and cytokine profiling of naive T cells stimulated by a tumor vaccine via CD3 and CD25. Nov 2010 - Int. J. Oncol.; 37(6):1791-2423 [PMID:21042712] [Fournier P] [Aigner M] [Schirrmacher V]
Optimization studies for the coupling of bispecific antibodies to viral anchor molecules of a tumor vaccine. Sep 2010 - Int. J. Oncol.; 37(5):1791-2423 [PMID:20878068] [Fournier P] [Aigner M] [Schirrmacher V]
The hemagglutinin-neuraminidase gene of Newcastle Disease Virus: A powerful molecular adjuvant for DNA anti-tumor vaccination. Aug 2010 - :1873-2518 [PMID:20709006] [Ni J] [Schirrmacher V] [Fournier P]
Activation of natural killer cells by newcastle disease virus hemagglutinin-neuraminidase. Jul 2009 - J. Virol.; 83(16):1098-5514 [PMID:19515783] [Jarahian M] [Watzl C] [Fournier P] [Arnold A] [Djandji D] [Zahedi S] [Cerwenka A] [Paschen A] [Schirrmacher V] [Momburg F]
Newcastle disease virus: a promising vector for viral therapy, immune therapy, and gene therapy of cancer. Jul 2009 - Methods Mol. Biol.; 542:1064-3745 [PMID:19565923] [Schirrmacher V] [Fournier P]
Treatment of advanced metastasized breast cancer with bone marrow-derived tumour-reactive memory T cells: a pilot clinical study. Apr 2009 - Cancer Immunol. Immunother.; 58(6):1432-0851 [PMID:18998129] [Schuetz F] [Ehlert K] [Ge Y] [Schneeweiss A] [Rom J] [Inzkirweli N] [Sohn C] [Schirrmacher V] [Beckhove P]
Expression of RIG-I, IRF3, IFN-beta and IRF7 determines resistance or susceptibility of cells to infection by Newcastle Disease Virus. Mar 2009 - Int. J. Oncol.; 34(4):1019-6439 [PMID:19287954] [Wilden H] [Fournier P] [Zawatzky R] [Schirrmacher V]
Cross-infection of tumor cells by contact with T lymphocytes loaded with Newcastle disease virus. Mar 2009 - Int. J. Oncol.; 34(4):1019-6439 [PMID:19287952] [Pfirschke C] [Schirrmacher V]
Efficiency of adjuvant active specific immunization with Newcastle disease virus modified tumor cells in colorectal cancer patients following resection of liver metastases: results of a prospective randomized trial. Oct 2008 - Cancer Immunol. Immunother.; 58(1):1432-0851 [PMID:18488223] [Schulze T] [Kemmner W] [Weitz J] [Wernecke KD] [Schirrmacher V] [Schlag PM]
Activation of human T cells by a tumor vaccine infected with recombinant Newcastle disease virus producing IL-2. Sep 2008 - Int. J. Oncol.; 33(4):1019-6439 [PMID:18813797] [Janke M] [Peeters B] [Zhao H] [de Leeuw O] [Moorman R] [Arnold A] [Ziouta Y] [Fournier P] [Schirrmacher V]
